Showing results (31-40 of 50) with videos related to
Sort By:
Pageof 5
The Journal of Rheumatology|August 13, 2009
Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centersBarry Bresnihan, Eliza Pontifex, Rogier M Thurlings, et al.Plos One|November 22, 2016
Functional Tissue Analysis Reveals Successful Cryopreservation of Human Osteoarthritic SynoviumMathijs G A Broeren, Marieke de Vries, Miranda B Bennink, et al.Trials|August 24, 2018
Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trialWieneke M T van den Hombergh, Brigit E Kersten, Hanneke K A Knaapen-Hans, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesisTineke Cantaert, Johanna Kolln, Trieneke Timmer, et al.Journal of Immunology Research|September 23, 2020
Selective Increment of Synovial Soluble TYRO3 Correlates with Disease Severity and Joint Inflammation in Patients with Rheumatoid ArthritisJulia Vullings, Juliana P Vago, Claire E J Waterborg, et al.BMJ Open|February 6, 2025
Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet's disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocolBettina C Geertsema-Hoeve, Jan A M van Laar, Joost Raaphorst, et al.Rheumatology (Oxford, England)|January 17, 2019
Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritisTamara H Ramwadhdoebe, Lisa G M van Baarsen, Maria J H Boumans, et al.Iscience|July 21, 2025
Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritisAnnika H Decker, Lucas L van den Hoogen, Tom van Oorschot, et al.Arthritis and Rheumatism|August 20, 2010
Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patientsRogier M Thurlings, Marie Boumans, Janneke Tekstra, et al.Rheumatology (Oxford, England)|June 10, 2022
Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cellsMerel A A Opdam, J H de Leijer, Nathan den Broeder, et al.Pageof 5